舒血宁注射液联合头孢哌酮钠舒巴坦钠对老年慢性心力衰竭并肺部感染患者的影响研究

Impact of Shuxuening Injection Combined with Cefoperazone Sodium and Sulbactam Sodium on Elderly Chronic Heart Failure Patients Complicated with Pulmonary Infection

目的探讨舒血宁注射液联合头孢哌酮钠舒巴坦钠(CPZ-SBT)对老年慢性心力衰竭(CHF)并肺部感染患者的影响。方法选取2017年10月—2018年10月合肥市滨湖医院收治的老年CHF并肺部感染患者112例,采用随机数字表法分为对照组和观察组,每组56例。在常规对症治疗基础上,对照组患者给予CPZ-SBT,观察组患者在对照组治疗基础上给予舒血宁注射液;两组患者均连续治疗2周。比较两组患者临床疗效,临床症状及体征(气喘、咳嗽、湿啰音)消失时间、退热时间,治疗前后呼吸频率、心率、动脉血气分析指标〔包括动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)〕、心功能指标〔包括左心室射血分数(LVEF)、B型利钠肽(BNP)〕、炎性反应指标〔包括降钙素原(PCT)、C反应蛋白(CRP)〕,并观察两组患者治疗期间不良反应发生情况。结果 (1)观察组患者临床疗效优于对照组(P<0.05)。(2)与对照组比较,观察组患者气喘、咳嗽、湿啰音消失时间及退热时间缩短(P<0.05)。(3)对照组与观察组患者治疗前呼吸频率及心率比较,差异无统计学意义(P>0.05);与对照组比较,观察组患者治疗后呼吸频率、心率降低(P<0.05)。(4)对照组与观察组患者治疗前PaO2、PaCO2比较,差异无统计学意义(P>0.05);与对照组比较,观察组患者治疗后PaO2升高,PaCO2降低(P<0.05)。(5)对照组与观察组患者治疗前LVEF、BNP比较,差异无统计学意义(P>0.05);与对照组比较,观察组患者治疗后LVEF升高,BNP降低(P<0.05)。(6)对照组与观察组患者治疗前PCT、CRP比较,差异无统计学意义(P>0.05);与对照组比较,观察组患者治疗后PCT、CRP降低(P<0.05)。(7)对照组与观察组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论舒血宁注射液联合CPZ-SBT可有效提高老年CHF并肺部感染患者临床疗效,缩短患者临床症状及体征缓解时间,改善患者心、肺功能,减轻患者炎性反应,且安全性较高。

Objective To investigate the impact of Shuxuening injection combined with Cefoperazone Sodium and Sulbactam Sodium(CPZ-SBT)on elderly chronic heart failure(CHF)patients complicated with pulmonary infection.Methods A total 112 elderly CHF patients complicated with pulmonary infection were selected in Binhu Hospital of Hefei from October 2017 to October 2018,and they were divided into control group and observation group according to random number table method,with 56 cases in each group.Based on routine symptomatic treatment,patients in control group were given CPZ-SBT,while patients in observation group were given Shuxuening injection combined with CPZ-SBT;both groups were treated continuously for 2 weeks.Comparisons of clinical effect,disappearance time of clinical symptoms and signs(including asthma,cough and moist crackles),antifebrile time,pre-and post-treatment respiratory rate,heart rate,arterial bloodgas analysis results(including PaO2 and PaCO2),index of cardiac function(including LVEF and BNP)and inflammatory reactions(including PCT and CRP)were conducted between the two groups,and incidence of adverse reactions was observed during treatment. Results (1)Clinical effect in observation group was statistically significantly better than that in controlgroup(P<0.05).(2)Disappearance time of asthma,cough and moist crackles,and antifebrile time in observation groupwere statistically significantly shorter than those in control group(P<0.05).(3)No statistically significant difference ofrespiratory rate or heart rate was found between the two groups before treatment(P>0.05),while respiratory rate and heartrate in observation group were statistically significantly lower than those in control group after treatment(P<0.05).(4)There was no statistically significant difference in PaO2 or PaCO2 between the two groups before treatment(P>0.05),PaO2 inobservation group was statistically significantly higher than that in control group after treatment,while PaCO2 was statisticallysignificantly lower(P<0.05).(5)There was no statistically significant difference in LVEF or BNP between the two groupsbefore treatment(P>0.05),LVEF in observation group was statistically significantly higher than that in control group aftertreatment,while BNP was statistically significantly lower(P<0.05).(6)There was no statistically significant difference inPCT or CRP between the two groups before treatment(P>0.05),while PCT and CRP in observation group were statisticallysignificantly lower compared with those in control group after treatment(P<0.05).(7)There was no statistically significantdifference in incidence of adverse reactions between the two groups during treatment(P>0.05). Conclusion Shuxueninginjection combined with CPZ-SBT can effectively improve the clinical effect in elderly CHF patients complicated with pulmonaryinfection,shorten the remission time of clinical symptoms and signs,improve the cardiac and pulmonary function,reduce theinflammatory reaction,and is relatively safe.